Abstract
BackgroundImmunotherapy with immune checkpoint inhibitor (ICI) is a promising treatment for unresectable hepatocellular carcinoma (HCC). However, whether ICIs would have the risk of hepatitis B virus (HBV) reactivation and the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have